Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients with recurrent, persistent or metastatic cervical cancer, according to late breaking results from the KEYNOTE-826 ...